Envestnet Asset Management Inc. Sells 13,925 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Envestnet Asset Management Inc. lessened its position in Emergent BioSolutions Inc. (NYSE:EBS) by 35.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,030 shares of the biopharmaceutical company’s stock after selling 13,925 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Emergent BioSolutions were worth $1,577,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Emergent BioSolutions by 6.3% in the 1st quarter. BlackRock Inc. now owns 5,608,476 shares of the biopharmaceutical company’s stock worth $521,084,000 after acquiring an additional 331,528 shares during the period. Janus Henderson Group PLC raised its holdings in Emergent BioSolutions by 192.3% in the 1st quarter. Janus Henderson Group PLC now owns 2,759,936 shares of the biopharmaceutical company’s stock worth $256,426,000 after acquiring an additional 1,815,872 shares during the period. Earnest Partners LLC increased its holdings in shares of Emergent BioSolutions by 5.1% during the 1st quarter. Earnest Partners LLC now owns 1,461,067 shares of the biopharmaceutical company’s stock worth $135,748,000 after purchasing an additional 70,332 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Emergent BioSolutions by 1.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,049,045 shares of the biopharmaceutical company’s stock worth $97,461,000 after purchasing an additional 12,231 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Emergent BioSolutions by 19.5% during the 1st quarter. Geode Capital Management LLC now owns 823,932 shares of the biopharmaceutical company’s stock worth $76,551,000 after purchasing an additional 134,198 shares during the period. Hedge funds and other institutional investors own 83.12% of the company’s stock.

EBS has been the topic of several research reports. Zacks Investment Research upgraded shares of Emergent BioSolutions from a “strong sell” rating to a “hold” rating and set a $65.00 price objective on the stock in a report on Tuesday, June 22nd. TheStreet lowered shares of Emergent BioSolutions from a “b-” rating to a “c” rating in a research report on Thursday, July 29th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Emergent BioSolutions has an average rating of “Buy” and an average target price of $90.20.

NYSE:EBS opened at $56.36 on Tuesday. The firm has a market cap of $3.03 billion, a PE ratio of 10.17 and a beta of 0.91. Emergent BioSolutions Inc. has a 12 month low of $55.07 and a 12 month high of $127.20. The company has a quick ratio of 2.05, a current ratio of 3.08 and a debt-to-equity ratio of 0.53. The company’s 50-day moving average price is $61.72 and its two-hundred day moving average price is $66.94.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, July 29th. The biopharmaceutical company reported $0.33 EPS for the quarter, missing the Zacks’ consensus estimate of $1.81 by ($1.48). The firm had revenue of $397.50 million during the quarter, compared to analyst estimates of $415.73 million. Emergent BioSolutions had a net margin of 17.51% and a return on equity of 29.10%. On average, research analysts expect that Emergent BioSolutions Inc. will post 8.17 EPS for the current fiscal year.

Emergent BioSolutions Profile

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.

See Also: Dividend Aristocrat Index

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.